A Study to Evaluate Safety and Efficacy of Convalescent Methylene Blue Treated (MBT) Plasma From Donors Recovered From Coronavirus Disease 2019 (COVID-19)

NCT04547127 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

200

Enrollment

INDUSTRY

Sponsor class

Conditions

COVID-19

Interventions

BIOLOGICAL: Convalescent anti-SARS-CoV-2 MBT Plasma
DRUG: Standard Medical Treatment

Sponsor

Instituto Grifols, S.A.